Reuters -- Vical Inc said it received a new U.S. patent covering its Vaxfectin-formulated DNA vaccines for seasonal and pandemic influenza, sending its shares up 26 percent in pre-market trade.
Reuters -- Vical Inc said it received a new U.S. patent covering its Vaxfectin-formulated DNA vaccines for seasonal and pandemic influenza, sending its shares up 26 percent in pre-market trade.
